NuvOx Therapeutics, Inc.

Overview

Compare with another stock.

• TickerNUOX¹
• IndustryPharmaceutical Preparations¹
• HeadquartersTucson, Arizona¹
• Incorporated inDE²
• Business address1635 E. 18Th Street, Tucson, Az 85719²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorEvan Unger named Feb 15, 2023 to Nov 22, 2024³
• Executive OfficerJennifer Johnson named Nov 22, 2024³
• Executive OfficerRong Wang named Feb 15, 2023 to Nov 22, 2024³
• DirectorJon Saxe named Feb 15, 2023 to Nov 22, 2024³
• DirectorJonathan T. Schilling named Feb 15, 2023 to Nov 22, 2024³
• DirectorMarvin J. Slepian named Feb 15, 2023 to Nov 22, 2024³
• DirectorRichard T. Carmona named Feb 15, 2023 to Nov 22, 2024³

Calendar

Drug trials and FDA: coming up

1. Jun 30, 2027Phase 2 trial readout expected Phase 2 trial of NanO2TM in Glioblastoma Multiforme: primary completion expected Jun 30, 2027 (ClinicalTrials.gov NCT03862430).⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

8 filings to the SEC since October 2021: 2 private raises, 6 other. The latest 8:

1. Oct 13, 2026S-1/A REGISTRATION STATEMENT EDGAR
2. Sep 16, 2026S-1/A REGISTRATION STATEMENT EDGAR
3. Jul 17, 2026S-1 REGISTRATION STATEMENT EDGAR
4. May 6, 2025DRS/A EDGAR
5. Apr 8, 2025DRS/A EDGAR
6. Dec 23, 2024DRS EDGAR
7. Nov 22, 2024D EDGAR
8. Feb 15, 2023D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Sep 10, 2024Raised $235,000 in a private offering of debt³ Form D: $7 million offered in all Form D
2. Jan 31, 2023Raised $1.1 million in a private offering of debt⁵ Form D: $5 million offered in all Form D

SEC filer profile

How NuvOx Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARNuvOx Therapeutics, Inc.¹
• CIK0001966126
• Employer ID (EIN)92-1680380¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address1635 E. 18Th Street, Tucson, AZ 85719¹
• Phone520-624-6688¹
• On EDGAR sinceFeb 15, 2023¹
• Filings8 in all: D (2), DRS/A (2), S-1/A (2), DRS (1), S-1 (1)¹